JP2019515027A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515027A5 JP2019515027A5 JP2019505138A JP2019505138A JP2019515027A5 JP 2019515027 A5 JP2019515027 A5 JP 2019515027A5 JP 2019505138 A JP2019505138 A JP 2019505138A JP 2019505138 A JP2019505138 A JP 2019505138A JP 2019515027 A5 JP2019515027 A5 JP 2019515027A5
- Authority
- JP
- Japan
- Prior art keywords
- binding fragment
- antigen
- hvegf
- hvegf antigen
- glycosylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022108815A JP2022153418A (ja) | 2016-04-15 | 2022-07-06 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| JP2024152809A JP2025000642A (ja) | 2016-04-15 | 2024-09-05 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323285P | 2016-04-15 | 2016-04-15 | |
| US62/323,285 | 2016-04-15 | ||
| US201762442802P | 2017-01-05 | 2017-01-05 | |
| US62/442,802 | 2017-01-05 | ||
| US201762450438P | 2017-01-25 | 2017-01-25 | |
| US62/450,438 | 2017-01-25 | ||
| US201762460428P | 2017-02-17 | 2017-02-17 | |
| US62/460,428 | 2017-02-17 | ||
| PCT/US2017/027650 WO2017181021A1 (en) | 2016-04-15 | 2017-04-14 | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022108815A Division JP2022153418A (ja) | 2016-04-15 | 2022-07-06 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019515027A JP2019515027A (ja) | 2019-06-06 |
| JP2019515027A5 true JP2019515027A5 (enExample) | 2020-05-28 |
Family
ID=60041925
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505138A Pending JP2019515027A (ja) | 2016-04-15 | 2017-04-14 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| JP2022108815A Pending JP2022153418A (ja) | 2016-04-15 | 2022-07-06 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| JP2024152809A Pending JP2025000642A (ja) | 2016-04-15 | 2024-09-05 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022108815A Pending JP2022153418A (ja) | 2016-04-15 | 2022-07-06 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| JP2024152809A Pending JP2025000642A (ja) | 2016-04-15 | 2024-09-05 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20190127455A1 (enExample) |
| EP (1) | EP3442577A4 (enExample) |
| JP (3) | JP2019515027A (enExample) |
| KR (2) | KR20240005973A (enExample) |
| AU (2) | AU2017250797A1 (enExample) |
| CA (1) | CA3019665A1 (enExample) |
| IL (1) | IL262277A (enExample) |
| SG (2) | SG10202008378UA (enExample) |
| WO (1) | WO2017181021A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| IL262207B2 (en) | 2016-04-15 | 2026-01-01 | Univ Pennsylvania | Preparations for the treatment of wet age-related macular degeneration |
| CA3076905A1 (en) * | 2017-09-27 | 2019-04-04 | The Johns Hopkins University | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| CA3086045A1 (en) * | 2017-12-19 | 2019-06-27 | Akouos, Inc. | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| US12558434B2 (en) * | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| IL313246B2 (en) * | 2018-06-28 | 2025-10-01 | Univ North Carolina Chapel Hill | Optimal cln5 expression genes and cassettes and their use |
| CN113853437A (zh) * | 2018-11-07 | 2021-12-28 | 阿库斯股份有限公司 | 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途 |
| EP4667578A3 (en) * | 2019-04-03 | 2026-04-01 | REGENXBIO Inc. | Gene therapy for eye pathologies |
| US20220195462A1 (en) * | 2019-04-24 | 2022-06-23 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| AU2020334924A1 (en) * | 2019-08-22 | 2022-04-07 | The Regents Of The University Of California | UBE3A for the treatment of Angelman syndrome |
| CA3149401A1 (en) | 2019-08-26 | 2021-03-04 | Stephen Joseph Pakola | Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab |
| WO2021071835A1 (en) | 2019-10-07 | 2021-04-15 | Regenxbio Inc. | Adeno-associated virus vector pharmaceutical composition and methods |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN113952474A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| EP4225381A1 (en) | 2020-10-07 | 2023-08-16 | RegenxBio Inc. | Formulations for suprachoroidal administration such as formulations with aggregate formation |
| TW202228648A (zh) | 2020-10-07 | 2022-08-01 | 美商銳進科斯生物股份有限公司 | 諸如高黏度調配物之用於脈絡膜上投與之調配物 |
| JP2023544803A (ja) | 2020-10-07 | 2023-10-25 | レジェンクスバイオ インコーポレーテッド | Ｃｌｎ２疾患の眼症状に対する遺伝子療法 |
| TW202228646A (zh) | 2020-10-07 | 2022-08-01 | 美商銳進科斯生物股份有限公司 | 諸如凝膠調配物之用於脈絡膜上投與之調配物 |
| AU2021371307A1 (en) * | 2020-10-28 | 2023-06-01 | Regenxbio, Inc. | VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| JP2024500115A (ja) * | 2020-12-18 | 2024-01-04 | エイシー イミューン ソシエテ アノニム | 抗体デリバリー |
| MX2023008826A (es) | 2021-02-01 | 2023-09-15 | Regenxbio Inc | Terapia génica para lipofuscinosis neuronal ceroidea. |
| US20250026833A1 (en) * | 2021-03-31 | 2025-01-23 | WuXi Biologics Ireland Limited | A bispecific anti-pd-l1/vegf antibody and uses thereof |
| US20260043046A1 (en) * | 2022-03-17 | 2026-02-12 | Adverum Biotechnologies, Inc. | Cassettes of anti-complement component 3 antibody, vectorization and theraputic application |
| TW202404651A (zh) | 2022-04-06 | 2024-02-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如形成聚集體之調配物 |
| TW202345913A (zh) | 2022-04-06 | 2023-12-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如凝膠調配物 |
| AU2023250660A1 (en) | 2022-04-06 | 2024-10-24 | Regenxbio Inc. | Pharmaceutical composition comprising a recombinant adenoassociated virus vector with an expression cassette encoding a transgene for suprachoroidal administration |
| EP4593955A1 (en) | 2022-09-30 | 2025-08-06 | RegenxBio Inc. | Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2388432A1 (en) * | 1999-10-21 | 2001-04-26 | Monsanto Company | Post-translational modification of recombinant proteins produced in plants |
| US20020068694A1 (en) * | 2000-07-26 | 2002-06-06 | Jeltsch Markku Michael | Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B |
| RU2567639C2 (ru) * | 2009-06-17 | 2015-11-10 | АббВай Биотерапеутикс Инк., | Антитела против vegf и их применения |
| US20130090375A1 (en) * | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
| TWI698240B (zh) * | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| CR20160519A (es) * | 2014-05-13 | 2017-01-27 | The Trustees Of The Univ Of Pennysylvania | Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos |
-
2017
- 2017-04-14 JP JP2019505138A patent/JP2019515027A/ja active Pending
- 2017-04-14 KR KR1020237043995A patent/KR20240005973A/ko not_active Ceased
- 2017-04-14 CA CA3019665A patent/CA3019665A1/en active Pending
- 2017-04-14 WO PCT/US2017/027650 patent/WO2017181021A1/en not_active Ceased
- 2017-04-14 AU AU2017250797A patent/AU2017250797A1/en not_active Abandoned
- 2017-04-14 US US16/093,363 patent/US20190127455A1/en not_active Abandoned
- 2017-04-14 SG SG10202008378UA patent/SG10202008378UA/en unknown
- 2017-04-14 KR KR1020187032191A patent/KR20190003556A/ko not_active Ceased
- 2017-04-14 EP EP17783242.5A patent/EP3442577A4/en active Pending
- 2017-04-14 SG SG11201808440YA patent/SG11201808440YA/en unknown
-
2018
- 2018-10-10 IL IL262277A patent/IL262277A/en unknown
-
2019
- 2019-03-22 US US16/361,884 patent/US20190211091A1/en not_active Abandoned
-
2022
- 2022-03-25 US US17/704,170 patent/US20230057519A1/en not_active Abandoned
- 2022-07-06 JP JP2022108815A patent/JP2022153418A/ja active Pending
-
2024
- 2024-08-09 AU AU2024205641A patent/AU2024205641A1/en active Pending
- 2024-09-05 JP JP2024152809A patent/JP2025000642A/ja active Pending